Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-14T12:12:05.082Z Has data issue: false hasContentIssue false
  • English
  • Français

Complete response in a melanoma patient treated with imatinib

Published online by Cambridge University Press:  19 April 2012

M C Brown and
R J Casasola
M C Brown
Affiliation:
Medical School, University of Dundee, Dundee, Scotland, UK
R J Casasola*
Affiliation:
Oncology Department, Ninewells Hospital, Dundee, Scotland, UK
*
Address for correspondence: Dr Richard J Casasola, Oncology Department, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK E-mail: rcasasola@nhs.net
Rights & Permissions [Opens in a new window]

Abstract

Background:

Imatinib therapy has been successful in gastrointestinal stromal tumours containing mutation of the KIT gene. However, there are few reported cases of successful imatinib therapy in patients with melanoma containing KIT gene mutation or c-kit protein expression.

Methods and results:

A 52-year-old man developed metastatic melanoma from a primary melanoma in the left side of the nasopharynx. The tumour was positive for c-kit protein, and there was a KIT mutation in exon 11. He was treated with imatinib. A follow-up scan one year later showed a complete response. Treatment targeting the biological characteristics of melanoma proved successful in this patient.

Keywords

MelanomaProto-OncogenesC-kit ProteinNasopharynxAntineoplastic Agents

Information

Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 126 , Issue 6 , June 2012, pp. 638 - 640
Copyright
Copyright © JLO (1984) Limited 2012

Introduction

Non-cutaneous melanomas are rare compared with cutaneous melanomas: over 90 per cent of melanomas arise from the skin.Reference Chang, Karnell and Menck1 Only 1.3 per cent of melanomas arise from mucosal sites.Reference Chang, Karnell and Menck1 Of the small number of mucosal melanomas, the majority are seen in the head and neck.Reference Chang, Karnell and Menck1 In the UK, the lifetime risk of developing melanoma is one in 77 for women and one in 91 for men.2 Metastatic melanoma has a poor prognosis, with a median survival of just six to 10 months.Reference Manola, Atkins, Ibrahim and Kirkwood3

The c-kit protein is involved in proliferation, migration and survival of melanocytes, therefore playing a vital role in melanocyte physiology. In the normal physiological state, the c-kit protein must be activated by stem cell factor; however, in tumours stem cell factor activation is not required for c-kit activation.Reference Rivera, Nagatsuka, Gunduz, Cengiz, Gunduz and Siar4

Expression of the c-kit protein has been previously reported in melanoma. However, the results of phase II trials of imatinib therapy in melanoma patients have been disappointing, showing little or no efficacy and significant toxicity.Reference Ugurel, Hildenbrand, Zimpfer, La Rosée, Paschka and Sucker5–Reference Kim, Eton, Davis, Frazier, McConkey and Diwan7

Imatinib selectively inhibits protein tyrosine kinases, including c-kit.Reference Buchdunger, Cioffi, Law, Stover, Ohno-Jones and Druker8 It has shown to be effective in treating other cancers which express mutant c-kit proteins, such as gastrointestinal stromal tumours.Reference Demetri, von Mehren, Blanke, Van den Abbeele, Eisenberg and Roberts9

Case report

A 52-year-old man presented to the ENT department with catarrh and rhinorrhoea. During examination under anaesthesia, a large tumour was seen in the left nasopharynx and a biopsy was taken. Histopathological analysis confirmed a diagnosis of malignant melanoma with no local spread and no nodal metastases. The patient underwent debulking of the tumour and radical radiotherapy via lateral radiation portals to the nasopharynx.

On follow up at 15 months, recurrence in the nasopharynx was treated with local excision.

At 23 months, the patient developed a mass involving the right latissimus dorsi muscle. This isolated mass was proven to be metastatic melanoma, and so the patient received radiotherapy to the right axilla. Molecular genetic testing was carried out on the lesion, which showed it to have a KIT gene exon 11 mutation, c1676T > A.

One month later, the patient developed a lesion on his right thigh. A fine needle aspirate biopsy confirmed this to be metastatic melanoma. This tumour was c-kit-positive. Staging investigations showed widespread cutaneous lesions as well as splenic and widespread abdominal involvement. Molecular genetic testing was carried out on the thigh lesion, showing it to have a KIT gene exon 11 mutation.

In view of this, and following discussion with the patient, imatinib therapy (400 mg daily) was commenced.

After one month of imatinib treatment, the lesions on the patient's neck and lower chest were not palpable on examination, and the lesion on his right thigh was barely palpable. No other abnormalities were detected, and there was no evidence of organomegaly or lymphadenopathy.

Three months after commencement of treatment, a follow-up computed tomography (CT) scan indicated a significant response, as shown in Figure 1.

Fig. 1

Axial computed tomography scans taken (a) before and (b) after commencement of imatinib treatment. R = right; P = posterior

Nine months after starting treatment, a further CT scan showed a complete response, with no evidence of recurrence.

The patient tolerated imatinib therapy well. The only side effect he complained of was mild peri-orbital oedema, which improved within three months.

At the time of writing, 18 months after commencement of treatment, the patient was continuing on imatinib therapy and remained in remission, with no evidence of recurrence.

Discussion

Imatinib is indicated as treatment for gastrointestinal stromal tumours with a KIT gene mutation, as clinical studies have identified either a response or stable disease in 75 to 90 per cent of patients.Reference van Oosterom, Judson, Verweij, Stroobants, Donato, Paola and Dimitrijevic10, Reference Verweij, Casali, Zalcberg, LeCesne, Reichardt and Blay11 KIT gene mutations have been identified in 75 to 80 per cent of gastrointestinal stromal tumours, suggesting the importance of such mutations for imatinib efficacy.Reference Rubin, Heinrich and Corless12 However, KIT gene mutations are seen in only 15–20 per cent of acral lentiginous or mucosal melanomas.Reference Torres-Cabala, Wang, Trent, Yang, Chen and Galbincea13–Reference Jiang, Zhou, Yuen, Corless, Heinrich and Fletcher16

Studies of both gastrointestinal stromal tumours and melanoma have indicated that KIT gene mutation and c-kit protein expression do not always correlate.Reference Beadling, Jacobson-Dunlop, Hodi, Le, Warrick and Patterson15, Reference Medeiros, Corless, Duensing, Hornick, Oliveira and Heinrich17 Medeiros et al. found that 4 per cent of gastrointestinal stromal tumours did not show c-kit protein expression.Reference Beadling, Jacobson-Dunlop, Hodi, Le, Warrick and Patterson15, Reference Medeiros, Corless, Duensing, Hornick, Oliveira and Heinrich17 In this study, all four patients with KIT gene mutation but without c-kit protein expression remained sensitive to imatinib. This suggests that imatinib therapy should still be considered for gastrointestinal stromal tumour treatment even if there is no evidence of c-kit protein expression. If this theory was applied to melanoma, patients should be screened for KIT gene mutation as well as c-kit protein expression, to take into consideration the fact that these may not always correlate.

It is interesting that the KIT gene mutation identified in our patient was in exon 11, as this is the most commonly seen mutation in gastrointestinal stromal tumours.Reference Rubin, Heinrich and Corless12 Mutations in exon 11 seem to be more sensitive to imatinib than other mutations.Reference Rubin, Heinrich and Corless12 Perhaps further studies of KIT gene mutations in melanoma will give more consistently promising results than have been obtained from investigation of c-kit protein expression.

  • • There are few reports of successful imatinib therapy for melanoma

  • • Such therapy is successful for gastrointestinal stromal tumours with KIT gene mutation or c-kit protein expression

  • • In the reported case of nasopharyngeal metastatic melanoma with KIT exon 11 mutation and c-kit expression, such therapy was successful

  • • Oncologists should consider biological therapies for melanoma patients with these biological characteristics

Our melanoma patient had a good outcome following imatinib therapy. Therefore, oncologists should be encouraged to explore such treatment in patients with melanomas expressing c-kit protein or containing a KIT gene mutation. With further research, it may be possible to identify which is the better prognostic predictor for imatinib therapy: KIT gene mutation or c-kit protein expression.

Acknowledgement

We thank Dr J Brunton for assistance in obtaining the CT images included in this report.

References

1Chang, AE, Karnell, LH, Menck, HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. Cancer 1998;83:1664–783.0.CO;2-G>CrossRefGoogle ScholarPubMed
2Cancer Research UK. Skin cancer – UK incidence statistics. In: http://info.cancerresearchuk.org/cancerstats/types/skin/incidence [29 November 2010]Google Scholar
3Manola, J, Atkins, M, Ibrahim, J, Kirkwood, J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782–93CrossRefGoogle ScholarPubMed
4Rivera, RS, Nagatsuka, H, Gunduz, M, Cengiz, B, Gunduz, E, Siar, CH et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008;452:27–32CrossRefGoogle ScholarPubMed
5Ugurel, S, Hildenbrand, R, Zimpfer, A, La Rosée, P, Paschka, P, Sucker, A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398–405CrossRefGoogle ScholarPubMed
6Wyman, K, Atkins, MB, Prieto, V, Eton, O, McDermott, DF, Hubbard, F et al. Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106:2005–11CrossRefGoogle ScholarPubMed
7Kim, KB, Eton, O, Davis, DW, Frazier, ML, McConkey, DJ, Diwan, AH et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008;99:734–40CrossRefGoogle ScholarPubMed
8Buchdunger, E, Cioffi, CL, Law, N, Stover, D, Ohno-Jones, S, Druker, BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139–45Google ScholarPubMed
9Demetri, GD, von Mehren, M, Blanke, CD, Van den Abbeele, AD, Eisenberg, B, Roberts, PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80CrossRefGoogle ScholarPubMed
10van Oosterom, AT, Judson, I, Verweij, J, Stroobants, S, Donato, diPaola, E, Dimitrijevic, S et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421–3CrossRefGoogle ScholarPubMed
11Verweij, J, Casali, PG, Zalcberg, J, LeCesne, A, Reichardt, P, Blay, JY et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127–34CrossRefGoogle ScholarPubMed
12Rubin, BP, Heinrich, MC, Corless, CL. Gastrointestinal stromal tumour. Lancet 2007;369:1731–41CrossRefGoogle ScholarPubMed
13Torres-Cabala, CA, Wang, WL, Trent, J, Yang, D, Chen, S, Galbincea, J et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009;22:1446–56CrossRefGoogle ScholarPubMed
14Curtin, JA, Busam, K, Pinkel, D, Bastian, BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340–6CrossRefGoogle ScholarPubMed
15Beadling, C, Jacobson-Dunlop, E, Hodi, FS, Le, C, Warrick, A, Patterson, J et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821–8CrossRefGoogle ScholarPubMed
16Jiang, X, Zhou, J, Yuen, NK, Corless, CL, Heinrich, MC, Fletcher, JA et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008;14:7726–32CrossRefGoogle ScholarPubMed
17Medeiros, F, Corless, CL, Duensing, A, Hornick, JL, Oliveira, AM, Heinrich, MC et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889–94CrossRefGoogle ScholarPubMed
Figure 0

Fig. 1Axial computed tomography scans taken (a) before and (b) after commencement of imatinib treatment. R = right; P = posterior